Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.

KURA

Kura Oncology (KURA)

Kura Oncology Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:KURA
DateTimeSourceHeadlineSymbolCompany
21/11/202409:21Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KURAKura Oncology Inc
21/11/202409:00PR Newswire (US)Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute LeukemiasNASDAQ:KURAKura Oncology Inc
21/11/202409:00GlobeNewswire Inc.Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute LeukemiasNASDAQ:KURAKura Oncology Inc
21/11/202409:00PR Newswire (US)Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute LeukemiasNASDAQ:KURAKura Oncology Inc
20/11/202408:05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
19/11/202408:03Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:KURAKura Oncology Inc
08/11/202408:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KURAKura Oncology Inc
08/11/202408:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KURAKura Oncology Inc
08/11/202408:05GlobeNewswire Inc.Kura Oncology Reports Third Quarter 2024 Financial ResultsNASDAQ:KURAKura Oncology Inc
06/11/202401:09GlobeNewswire Inc.Kura Oncology to Present Updated Data from KOMET-007 Combination Trial of Ziftomenib at ASH Annual MeetingNASDAQ:KURAKura Oncology Inc
31/10/202422:30GlobeNewswire Inc.Kura Oncology to Report Third Quarter 2024 Financial ResultsNASDAQ:KURAKura Oncology Inc
24/10/202422:30GlobeNewswire Inc.Kura Oncology Reports Preclinical Data Supporting Opportunity for Ziftomenib in Treatment of Gastrointestinal Stromal Tumors (GIST)NASDAQ:KURAKura Oncology Inc
23/10/202422:30GlobeNewswire Inc.Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS InhibitorsNASDAQ:KURAKura Oncology Inc
01/10/202408:30GlobeNewswire Inc.Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet OncologyNASDAQ:KURAKura Oncology Inc
18/09/202406:10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
18/09/202406:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
18/09/202406:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KURAKura Oncology Inc
17/09/202421:30GlobeNewswire Inc.Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of DirectorsNASDAQ:KURAKura Oncology Inc
10/09/202421:30GlobeNewswire Inc.Kura Oncology to Participate in Cantor Global Healthcare ConferenceNASDAQ:KURAKura Oncology Inc
09/08/202406:15Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KURAKura Oncology Inc
09/08/202406:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KURAKura Oncology Inc
09/08/202406:05GlobeNewswire Inc.Kura Oncology Reports Second Quarter 2024 Financial ResultsNASDAQ:KURAKura Oncology Inc
08/08/202421:30GlobeNewswire Inc.Kura Oncology Announces FDA Clearance of IND Application for Menin Inhibitor Ziftomenib in Advanced Gastrointestinal Stromal Tumors (GIST)NASDAQ:KURAKura Oncology Inc
01/08/202421:30GlobeNewswire Inc.Kura Oncology to Report Second Quarter 2024 Financial ResultsNASDAQ:KURAKura Oncology Inc
05/07/202421:30GlobeNewswire Inc.Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KURAKura Oncology Inc
24/06/202421:30GlobeNewswire Inc.Kura Oncology Reports Preclinical Data Supporting Potential for Menin Inhibitor in DiabetesNASDAQ:KURAKura Oncology Inc
08/06/202406:30Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KURAKura Oncology Inc
08/06/202406:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
08/06/202406:30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KURAKura Oncology Inc
08/06/202406:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KURAKura Oncology Inc
 Showing the most relevant articles for your search:NASDAQ:KURA